Summary:
AIxMed and Lumea have partnered to integrate AIxMed’s urine cytology diagnostic tool, AIxURO, into Lumea’s digital pathology platform, enhancing diagnostic capabilities for bladder cancer in the urology market.
Takeaways:
- Partnership Expansion: Lumea is incorporating AIxMed’s AIxURO to expand its digital pathology AI offerings specifically for urine cytology.
- Clinical Benefits: AIxURO supports non-invasive bladder cancer diagnostics by identifying abnormal cells and improving workflow efficiency.
- Market Reach: The integration targets a broad segment of the U.S. urology market, aiming to streamline diagnostics and reduce reliance on invasive procedures.
AIxMed, an provider of AI diagnostics for urine cytology, and Lumea, a provider of primary clinical digital pathology solutions, have formed a new partnership. This collaboration will integrate AIxMed’s specialized AI technology into Lumea’s FDA-cleared digital pathology platform, broadening the advanced diagnostic tools available to the urology market.
“We are pleased to partner with AIxMed and add their expertise in urine cytology AI to our growing portfolio of AI solutions,” says James Thackeray, CEO of Lumea. “This partnership reflects our ongoing commitment to integrating valuable AI capabilities that meet the specific needs of our diverse customer base and enhance diagnostic pathways.”
AlxURO Is Designed to Assist in Analysis of Urine Cytology Specimens
AIxMed’s solution AIxURO is designed to assist in the analysis of non-invasive urine cytology specimens, aiming to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment. AIxURO accurately identifies suspicious and atypical cells from a non-invasive urine sample incorporating The Paris System (TPS) for Reporting Urinary Cytology. These features are intended to support clinical decision-making, potentially reducing the frequency of invasive procedures like cystoscopies, enhancing patient compliance, and contributing to more cost effective healthcare.
“We recognize Lumea as a leader in providing an end-to-end solution for the urology market,” says Samuel Chen, CEO of AIxMed. “We are excited to provide an integrated and tested solution within their platform allowing our mutual customers the ability to triage their cases, improve their QC, and make their work more efficient.”
AlxURO Will Be Integrated into Digital Pathology Ecosystem
Lumea will integrate AIxURO into its established digital pathology ecosystem, which is utilized by a significant portion of the U.S. urology market. The addition of this urine cytology AI further diversifies Lumea’s offerings for urologists and strengthens its support for comprehensive cancer diagnostic workflows. To learn more about these solutions or to request a demonstration, please visit www.lumeadigital.com or www.aixmed.com.
Featured Image: Luchschen | Dreamstime.com
